Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study Of CNTY-101 At ASCO 2024 Annual Meeting In patients with Relapsed or Refractory, CD19-Positive B-Cell Malignancies

Benzinga · 06/03 11:08
  • In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting.
  • Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels.
  • Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream.
  • Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 billion cells) per cycle.